Weekly OHDSI Digest - 12Jun2017

MauraBeaton · June 12, 2017, 7:52pm

OHDSI MEETINGS THIS WEEK

Patient-level prediction (Western hemisphere) WG meeting - Wednesday at 12pm ET
https://global.gotomeeting.com/join/9729176611

Population-Level Estimation (Eastern hemisphere) WG Meeting - Wednesday at 3pm Hong Kong time
https://meetings.webex.com/collabs/#/meetings/detail?uuid=M6WE9AOKFETH2VEFPVCZWWBIT0-D1JL&rnd=479368.763622

NLP workgroup meeting - Wednesday at 2pm ET
Dial +1 (571) 317-3122 (United States)
Enter conference ID: 707-196-421
Screen Sharing: https://global.gotomeeting.com/join/707196421

Architecture WG meeting - Thursday at 1pm ET
Webex: https://jjconferencing.webex.com/mw3000/mywebex/default.do?service=1&main_url=%2Fmc3000%2Fe.do%3Fsiteurl%3Djjconferencing%26AT%3DMI%26EventID%3D283835502%26MTID%3Dmb7e839a762fbdaab0608f27500679223%26Host%3DQUhTSwAAAASTOYBxx2KWYTIL7ZSgHgHJoIHctjgxp8k5mgqAEPo2a1ESa12-8hjAVWbZznuDt96ugkT31G8sY5iSWLRwSwhI0%26FrameSet%3D2&siteurl=jjconferencing&nomenu=true

ANNOUNCEMENTS

No OHDSI call this week - Tomorrow’s OHDSI call (12-1pm ET) has been cancelled. Our next call will be June 20th.

2017 OHDSI Symposium - The date and location for the 2017 OHDSI Symposium has been confirmed! This year’s symposium will take place on Wednesday, October 18th at the Bethesda North Marriott. Full-day tutorial sessions will take place on October 19-20th. Registration for the symposium here: https://www.ohdsi.org/symposium-registration/

Call for Sponsorship - To fund the 2017 symposium we need to raise $200K to cover operating costs of venue rental, lunch, audio/visuals and recordings fees. We’re reaching out to the entire community for sponsors who want to support this important event and allow us to build upon the success of past symposia. More details: OHDSI Symposium 2017 - call for sponsorship

Training opportunity - The Center for Pharmacoepidemiology Research and Training is offering a free seminar series on drug-drug interactions: http://mailchi.mp/mail/the-health-effects-of-drug-drug-interactions-a-webinar-series?e=3ea48f19e7

Wise men speak because they have something to say; Fools because they have to say something.

Plato

COMMUNITY PUBLICATIONS

Building a semantic web-based metadata repository for facilitating detailed clinical modeling in cancer genome studies

Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available.

ncbi.nlm.nih.gov

Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available.

M Samwald, H Xu, K Blagec, PE Empey, DC Malone, SM Ahmed, P Ryan, S Hofer and RD Boyce, PloS one, 2016

Pre-emptive pharmacogenomic (PGx) testing of a panel of genes may be easier to implement and more cost-effective than reactive pharmacogenomic testing if a sufficient number of medications are covered by a single test and future medication exposure can be anticipated. We analysed the incidence of exposure of individual patients in the United States to multiple drugs for which pharmacogenomic guidelines are available (PGx drugs) within a selected four-year period (2009-2012) in order to identify and quantify the incidence of pharmacotherapy in a nation-wide patient population that could be impacted by pre-emptive PGx testing based on currently available clinical guidelines. In total, 73 024 095 patient records from private insurance, Medicare Supplemental and Medicaid were included. Patients enrolled in Medicare Supplemental age > = 65 or Medicaid age 40-64 had the highest incidence of PGx drug use, with approximately half of the patients receiving at least one PGx drug during the 4 year period and one fourth to one third of patients receiving two or more PGx drugs. These data suggest that exposure to multiple PGx drugs is common and that it may be beneficial to implement wide-scale pre-emptive genomic testing. Future work should therefore concentrate on investigating the cost-effectiveness of multiplexed pre-emptive testing strategies.